Bob Zutaut, RPh
Advertisement
Bob Zutaut, RPh, is director of clinical services at McKesson.
Articles by Bob Zutaut, RPh
Expanding operations to provide specialty infusions can provide benefits to both patients and oncology practices.
Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.
Advertisement
Latest Updated Articles
Offering Specialty Infusions May Be Worth the Work for Oncology PracticesPublished: November 7th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
